{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Cardiol Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"CRDL"},"Address":{"label":"Address","value":"2265 UPPER MIDDLE ROAD EAST,SUITE 602, OAKVILLE, Ontario, L6H 0G5, Canada"},"Phone":{"label":"Phone","value":"+1 289 910-0850"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure."},"CompanyUrl":{"label":"Company Url","value":"https://www.cardiolrx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Andrew Hamer","title":"Chief Medical Officer, Head-Research & Development"},{"name":"Bernard Lim","title":"Chief Operating Officer"},{"name":"David G. Elsley","title":"President, Chief Executive Officer & Director"},{"name":"Kelly Narine","title":"Director-Medical Affairs"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}